leukemia

[Blood] Scientists reported the results of a multicenter, open-label, Phase I/II study of flotetuzumab in 88 adults with relapsed/refractory AML: 42 in a dose-finding segment and 46 at the recommended Phase II dose of 500 ng/kg per day.

[Haematologica] Investigators evaluated the response to inotuzumab ozogamicin in 31 relapsed/refractory B cell acute lymphoblastic leukemia patients with extramedullary disease.

[Cell Reports] Aberrant genomic localization of DOT1L was implicated in mixed lineage leukemia-rearranged leukemias, an aggressive subset of leukemias that lacks effective targeted treatments.

[EMBO Journal] Researchers revealed Pax5-Jak2 as an important nuclear driver of leukemogenesis by maintaining phosphorylated STAT5 levels in the nucleus.

[Scientific Reports] Investigators explored the presence of cell-surface associated glucose regulated proteins (GRP78) in pediatric B-ALL at diagnosis and investigated the correlation with bona fide markers of leukemia.

[Cell Death & Disease] The authors showed that impaired miR-652-5p expression inhibited growth, promoted apoptosis of T lymphoblastic leukemia cells in vitro and prolonged overall survival in vivo/em>.